Acupuncture for bevacizumab-related paralysis and changes in peripheral lymphocyte cells in advanced lung adenocarcinoma

Patients might experience severe adverse reactions during anti-tumor therapy, which seriously affect the quality of life and need to be closely monitored. Chemotherapy with platinum-based drugs, taxanes and other cytotoxic agents may trigger extremely rare and severe nerve damage, potentially leading to the serious consequence of paralysis. Bevacizumab, when administered in combination with chemotherapy agents, may exacerbate neurotoxicity, potentially leading to paralysis.In this case report, a patient with lung adenocarcinoma experienced peripheral paresthesia affecting hands and feet after initial treatment with paclitaxel, nedaplatin, and sintilimab, and rapid progression to paralysis due to neurotoxic effects after switching to bevacizumab combined with osimertinib.While standard therapies for severe paralysis typically fail to yield significant functional improvements, this patient experienced marked symptom relief after acupuncture, together with demonstrable down-regulation of systemic inflammation and immunosuppression.This case report indicates the need for clinical caution when using bevacizumab to avoid exacerbating chemotherapy's adverse effects. Additionally, acupuncture may serve as a complementary approach for mitigating severe adverse events experienced by cancer patients, and changes in peripheral lymphocyte subsets (e.g., CD4+/CD8 + T-cell ratios) may be closely associated with efficacy and prognosis.